166 results
8-K
EX-99.1
ACGN
Aceragen Inc
6 Mar 07
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results
12:00am
to a reimbursement of third party expenses in 2005 as part of the Company’s collaboration with Novartis, offset in part by license fees recognized under … incurred by the Company in 2005 related to the Novartis collaboration and lower clinical trial expenses in 2006, offset in part by higher payroll costs
8-K
EX-99.1
ACGN
Aceragen Inc
4 Mar 08
Results of Operations and Financial Condition
12:00am
drug development efforts. The increase was offset, in part, by a decrease in IMO-2125 manufacturing costs.
General and administrative expenses … & Co.. The increase was partially offset by a decrease in license fee revenue recognized under the Company’s collaboration agreement with Novartis
8-K
bffr6 9et6tq41sbw
30 Jun 00
Current report
12:00am